Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors

Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors

Veteran biopharmaceutical executive brings extensive commercial and product launch expertise

Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Todd Smith as an independent director on the Company’s board of directors. Mr. Smith is chief executive officer (CEO) of Corium and brings more than three decades of executive leadership and commercial experience across the biotechnology and pharmaceutical industries.

“Todd’s extensive commercial expertise with launching numerous innovative biopharmaceutical products comes at an important time for Latigo,” said Nima Farzan, CEO of Latigo. “We are excited to add his strategic insight and proven track record of commercial execution to our board.”

“Todd is an accomplished biopharmaceutical executive with deep expertise in commercialization, business development and corporate strategy,” said Tim Walbert, chair of Latigo’s board of directors. “His experience bringing innovative medicines to patients and building high-performing organizations will be invaluable.”